Theravance To Slash Headcount By 75% After Latest Clinical Trial Setback

 
• By Joseph Haas
  
Business reengineering
Theravance will try an overhaul focused on respiratory disease to stay viable
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business